Affinage

RBM10

RNA-binding protein 10 · UniProt P98175

Length
930 aa
Mass
103.5 kDa
Annotated
2026-06-10
84 papers in source corpus 35 papers cited in narrative 35 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RBM10 is a nuclear RNA-binding protein that functions principally as an alternative splicing regulator, binding pre-mRNA near splice sites to promote exon skipping across a large set of target transcripts (PMID:24000153, PMID:27763814). It is a subunit of the U2 snRNP, associating with precatalytic A/B-like spliceosomes at intronic branch sites genome-wide through a conserved zinc-finger-containing peptide whose deletion abolishes U2 association and splicing repression activity (PMID:38537639). High-fidelity target recognition arises from cooperative RNA binding by tandem RRM1, ZnF1, and RRM2 domains: the RRM1-ZnF module reads a GGA-centered exonic motif while RRM2 recognizes C-rich intronic sequence, and the combined module binds target RNA with nanomolar affinity versus micromolar affinity for isolated domains (PMID:28379442, PMID:29450990); an additional OCRE domain forms a distinct β-stranded fold implicated in spliceosomal protein interactions (PMID:26712279). Through these activities RBM10 controls splicing of genes governing proliferation, apoptosis, and differentiation, including exon 9 skipping of NUMB to suppress Notch-driven proliferation (PMID:26853560), Fas and Bcl-x splicing to set apoptotic isoform balance (PMID:24530524, PMID:35579943), Dnmt3b isoform choice to modulate NF-κB-responsive DNA methylation (PMID:29309623), and hTERT exon exclusion to limit telomerase activity (PMID:33520366). RBM10 also negatively autoregulates its own expression and cross-regulates its paralog RBM5 via alternative-splicing-coupled nonsense-mediated decay (PMID:28586478). Beyond canonical splicing, RBM10 performs splicing-independent roles: it assembles the non-canonical poly(A) polymerase Star-PAP complex via RRM2 binding to direct 3'-end mRNA processing of anti-hypertrophy transcripts in the heart, an activity gated by cSrc phosphorylation at Y81/Y500/Y971 (PMID:30257214, PMID:34576144, PMID:38309577); it stabilizes DNA replication forks by associating with PRIM1 and recruiting HDAC1 for H4K16 deacetylation, with RBM10 deficiency being synthetically lethal with WEE1 inhibition (PMID:39080280); and it acts in antiviral defense by binding viral RNA and being targeted for proteasomal degradation by dengue NS5 and HIV-1 Vpu (PMID:32432721, PMID:40742131). Loss-of-function mutations in RBM10, including LUAD-associated splice-site and RRM2 mutations and a cholangiocarcinoma C2H2 zinc-finger C761Y mutation that disrupts SRSF2 interaction, impair its splicing activity and promote tumorigenesis (PMID:26853560, PMID:28586478, PMID:38576051), and RBM10 splicing defects were confirmed in a patient carrying an RBM10 mutation (PMID:24000153).

Mechanistic history

Synthesis pass · year-by-year structured walk · 35 steps
  1. 1996 Medium

    Before functional characterization, the gene's chromosomal identity was established, placing DXS8237E/RBM10 at Xp11.23 and showing it is subject to X inactivation.

    Evidence cDNA cloning and X-inactivation assay in somatic cell hybrids carrying an inactive X chromosome

    PMID:8808293

    Open questions at the time
    • No protein function assigned at this stage
    • No RNA-binding or splicing activity tested
  2. 2013 High

    The core function was defined: RBM10 binds pre-mRNA near splice sites and acts as an alternative-splicing regulator promoting exon skipping, with disease relevance shown through patient-derived splicing defects.

    Evidence PAR-CLIP binding-site mapping, KD/OE and minigene assays in human cells, plus patient cell analysis

    PMID:24000153

    Open questions at the time
    • Domain basis of RNA recognition not yet resolved
    • Spliceosomal context of action unknown
  3. 2013 Medium

    Nuclear access of RBM10 was shown to require three cooperative NLSs, establishing that its function depends on regulated nuclear import.

    Evidence Deletion/substitution mutagenesis and EGFP/FLAG reporter localization imaging

    PMID:23294349

    Open questions at the time
    • Import receptors not identified
    • Mechanism of cell-type-specific regulation unresolved
  4. 2014 Medium

    RBM10 was linked to apoptotic isoform control by directing Fas exon skipping and Bcl-x 5'-splice-site selection, with a proposed consensus binding motif.

    Evidence Minigene assays, KD/OE, and RT-PCR in human cell lines

    PMID:24530524

    Open questions at the time
    • Direct binding to these targets not structurally validated here
    • Physiological apoptotic consequence not tested in vivo
  5. 2015 High

    The OCRE motif was shown to fold into a discrete β-stranded globular domain distinct from RRMs, implicating it in spliceosomal protein-protein interactions rather than RNA binding.

    Evidence NMR structure determination of the OCRE domain

    PMID:26712279

    Open questions at the time
    • Specific protein partners of OCRE not identified
    • Functional requirement for splicing not tested
  6. 2016 High

    RBM10 was connected to growth control via NUMB exon 9 skipping to suppress Notch signaling, and cancer mutations were shown to uncouple RNA binding from splicing activity.

    Evidence Xenograft assays, minigene and RNA-binding assays, structural modeling, mutation analysis (including V354E)

    PMID:26853560

    Open questions at the time
    • Mechanism by which V354E disrupts splicing without abolishing binding unresolved
    • Generality across other targets not addressed
  7. 2016 High

    Transcriptome-wide binding and KO analysis in a developmental model confirmed preferential intronic binding and a requirement for RBM10 in proliferation and differentiation, while binding to U2/U12 snRNAs hinted at a spliceosomal association.

    Evidence iCLIP, KO RNA-seq, CRISPR/Cas9 KO, proliferation and differentiation assays in mouse cells

    PMID:27763814

    Open questions at the time
    • Direct snRNP incorporation not yet demonstrated biochemically
    • Developmental phenotype mechanism not dissected
  8. 2016 Medium

    A cytoplasmic, splicing-independent role was uncovered: Fyn-driven RBM10 translocation to the cell periphery supports FilGAP RacGAP activity controlling cell spreading and ruffling.

    Evidence Co-IP, siRNA KD, immunofluorescence, cell spreading/ruffle assays, kinase-dead Fyn mutant

    PMID:26751795

    Open questions at the time
    • Single-lab Co-IP without reciprocal structural mapping
    • Physiological significance of cytoplasmic pool unclear
  9. 2017 High

    RBM10 was shown to autoregulate its own expression and cross-regulate RBM5 through AS-coupled NMD, defining a feedback architecture relevant to LUAD mutations.

    Evidence Computational analysis, RT-PCR/qPCR, minigene assays, NMD inhibition, patient mutation analysis

    PMID:28586478

    Open questions at the time
    • Quantitative contribution of feedback to homeostasis unresolved
    • Trigger for differential exon choice unknown
  10. 2017 High

    The structural logic of target recognition was established: RRM1-ZnF reads an exonic GGA motif and RRM2 reads C-rich intronic sequence, with domain cooperativity giving high-affinity, high-fidelity binding.

    Evidence NMR structures of RRM1/ZnF1/RRM2, in vitro binding, domain dissection, splicing reporters

    PMID:28379442

    Open questions at the time
    • How motif engagement translates to spliceosome modulation not fully defined
    • OCRE contribution not integrated
  11. 2017 High

    RBM10 was tied to epigenetic and inflammatory output through Dnmt3b isoform control, linking splicing to NF-κB-responsive promoter methylation.

    Evidence Splicing RT-PCR, ChIP, methylation assay, NF-κB reporter, RBM10 KO mice

    PMID:29309623

    Open questions at the time
    • Direct binding to Dnmt3b pre-mRNA not mapped
    • Breadth of methylation changes not genome-wide
  12. 2017 Medium

    RBM10 was shown to influence SMN2 exon 7 inclusion, raising potential relevance to spinal muscular atrophy splicing, with rescue confirming specificity.

    Evidence siRNA KD, splicing array RT-PCR, Western blot, re-expression rescue, SMA patient fibroblasts

    PMID:28728573

    Open questions at the time
    • Direct binding to SMN2 not demonstrated
    • Single-lab observation
  13. 2017 Medium

    Context-dependent regulation was revealed: in an RBM5-null SCLC background, RBM5 post-transcriptionally regulates specific RBM10 splice variants and RBM10 promotes rather than suppresses proliferation.

    Evidence RIP-Seq, Western blotting, transcriptome and proliferation assays

    PMID:28662214

    Open questions at the time
    • Mechanism of context-dependent reversal of growth effect unclear
    • Single cell-line context
  14. 2018 High

    Cooperative tri-domain RNA recognition was quantitatively confirmed, showing nanomolar Fas-exon-6 binding by RRM1-ZnF1-RRM2 versus micromolar by single domains, and structural integrity of the V354del RRM2.

    Evidence NMR structures and quantitative in vitro binding affinity measurements

    PMID:29450990

    Open questions at the time
    • Structure of the full tri-domain-RNA complex not solved
    • Dynamics of cooperative assembly not resolved
  15. 2018 High

    A major splicing-independent function was defined in the heart: RBM10 assembles and directs the Star-PAP 3'-end processing complex toward anti-hypertrophy transcripts, with loss promoting hypertrophy.

    Evidence Reciprocal Co-IP, RRM2 domain mapping, 3'-end processing assays, H9c2 KD/OE, rat cardiac hypertrophy model

    PMID:30257214

    Open questions at the time
    • Full set of Star-PAP target mRNAs not enumerated here
    • Relationship between splicing and 3'-processing roles unresolved
  16. 2019 Medium

    A signaling axis was proposed for tumor suppression: RBM10 dampens RAP1/AKT/CREB signaling to limit LUAD proliferation, independent of MAPK pathways.

    Evidence Microarray, OE/KD, EPAC pharmacological epistasis, Western blot, in vitro/in vivo proliferation

    PMID:30955253

    Open questions at the time
    • Whether the effect is splicing-mediated not established
    • Direct molecular link between RBM10 and RAP1 unknown
  17. 2020 High

    RBM10 was assigned antiviral function: dengue NS5 degrades it, and RBM10 controls SAT1 splicing while binding viral RNA and promoting activating RIG-I ubiquitination.

    Evidence Co-IP, proteasome inhibitor rescue, KD/OE in infected cells, splicing RT-PCR, RIG-I ubiquitination assay

    PMID:32432721

    Open questions at the time
    • Mechanism of RIG-I ubiquitin transfer not defined
    • Direct E3 ligase activity of RBM10 not demonstrated
  18. 2020 Medium

    Upstream control of RBM10 levels was shown through miR-335 targeting its 3'UTR, linking RBM10 downregulation to NUMB-L accumulation and tumor growth.

    Evidence Luciferase reporter, Western blot, xenograft, NUMB splicing RT-PCR

    PMID:31894898

    Open questions at the time
    • Other regulatory inputs to RBM10 not surveyed
    • Single-context observation
  19. 2021 Medium

    Sequestration of RBM10 into S1-1 nuclear bodies was shown to regulate its splicing activity, with two NBTSs and a requirement of the C2H2 ZnF for both NB targeting and splicing.

    Evidence Deletion mutagenesis, reporter constructs, immunofluorescence, transcription inhibition

    PMID:34638866

    Open questions at the time
    • Physiological signals controlling NB sequestration unknown
    • Composition of S1-1 NBs not defined
  20. 2021 Medium

    A nuclear, splicing-independent role in centriole control was revealed: nuclear RBM10 sequesters PLK4/STIL/SAS6 to restrain centriole duplication in a cell-type-specific manner.

    Evidence HepG2 KO and inducible re-expression, flow cytometry, centriole-marker imaging, NES mutant

    PMID:31820547

    Open questions at the time
    • Direct binding to centriole regulators not shown
    • Basis of HepG2-versus-A549 specificity unknown
  21. 2021 Medium

    RBM10's contribution to 3'-end processing was generalized: it is globally required for Star-PAP mRNA association and target 3'-end processing.

    Evidence HITS-CLIP of Star-PAP, RBM10 KD, 3'-end processing and stability assays

    PMID:34576144

    Open questions at the time
    • Single-lab dataset
    • Overlap with splicing targets not resolved
  22. 2021 Medium

    An m6A regulatory role was reported: RBM10 binds MALAT1 and recruits METTL3 to alter MALAT1 m6A and PI3K/AKT/mTOR signaling, suppressing NSCLC invasion.

    Evidence CLIP-Seq, RIP, MeRIP-qPCR, Co-IP with METTL3, transwell assays

    PMID:36608868

    Open questions at the time
    • Mechanistic link between m6A change and signaling not fully established
    • Single-lab study
  23. 2021 Medium

    A splicing-independent heterochromatin function emerged from the fission yeast ortholog, which associates with the Clr6 HDAC complex and is required for heterochromatin silencing.

    Evidence Proteomics, Clr6 ChIP-seq, deep RNA-seq, genetic deletion, silencing reporters

    PMID:33468217

    Open questions at the time
    • Conservation of this role in human RBM10 not demonstrated
    • Direct Clr6/HDAC binding interface not mapped
  24. 2022 High

    RBM10's Bcl-x splicing role was tied to therapy response: deficiency lowers the Bcl-xS/Bcl-xL ratio, conferring EGFR-inhibitor resistance reversible by Bcl-xL co-inhibition.

    Evidence Patient-derived EGFR-mutant models, Bcl-x isoform RT-PCR, apoptosis assays, genetic inactivation, pharmacological rescue

    PMID:35579943

    Open questions at the time
    • Direct RBM10 binding to Bcl-x not re-mapped here
    • Generalizability across EGFR genotypes not fully tested
  25. 2022 Low

    RBM10 was shown to regulate NPTX1 mRNA stability, extending its post-transcriptional repertoire beyond splicing.

    Evidence RIP assay and actinomycin D mRNA decay experiments in pancreatic cancer cells

    PMID:35836482

    Open questions at the time
    • Single RIP plus stability experiment without reciprocal validation
    • Mechanism of stability control undefined
  26. 2023 Medium

    RBM10 was shown to suppress telomerase by excluding hTERT exons 7/8 to produce the inactive hTERT-s isoform, affecting pancreatic cancer growth.

    Evidence RNA-IP, RNA pulldown, minigene/splicing assays, OE/KD, telomerase assay, xenograft

    PMID:33520366

    Open questions at the time
    • Binding-site mapping limited
    • Single-lab study
  27. 2024 High

    The biochemical basis of RBM10's spliceosomal action was established: it (with RBM5) is a U2 snRNP subunit binding precatalytic spliceosomes at branch sites via a conserved zinc-finger peptide required for exon repression.

    Evidence Chromatin-associated RNP isolation, MS proteomics, branch-site sequencing, domain deletion, splicing reporters

    PMID:38537639

    Open questions at the time
    • Structural detail of the RBM10-U2 contact not solved
    • How U2 association drives exon skipping mechanistically unresolved
  28. 2024 High

    The cardiac Star-PAP function was shown to be switched on by cSrc phosphorylation of RBM10 at Y81/Y500/Y971, which drives nuclear localization and Star-PAP binding needed to reverse hypertrophy.

    Evidence In vitro kinase assay, Y-to-F phospho-deficient mutants, cSrc inhibitor, isoproterenol rat heart model, Co-IP, localization assay

    PMID:38309577

    Open questions at the time
    • Whether these sites affect splicing functions not tested
    • Upstream activator of cSrc in this context unclear
  29. 2024 High

    A splicing-independent role in replication fork stability was defined: RBM10 binds active forks via PRIM1, recruits HDAC1 for H4K16 deacetylation and R-loop control, and its loss is synthetically lethal with WEE1 inhibition.

    Evidence CRISPR-Cas9 synthetic lethality screen, DNA fiber assay, iPOND proteomics, HDAC1 recruitment, H4K16 ChIP, R-loop quantification, in vivo WEE1 inhibitor

    PMID:39080280

    Open questions at the time
    • RNA-dependence of fork association not fully separated from protein interactions
    • Direct PRIM1 binding interface not mapped
  30. 2024 High

    A cholangiocarcinoma driver mechanism was defined: RBM10-SRSF2 cooperation promotes ASPM exon 18 skipping, and the C2H2 ZnF C761Y mutation disrupts SRSF2 binding to enhance Wnt/β-catenin signaling.

    Evidence RNA-seq, minigene reporters, Co-IP of WT vs C761Y with SRSF2, Western blot, tumor assays

    PMID:38576051

    Open questions at the time
    • Generality of SRSF2 partnership across targets unknown
    • Structural basis of C761Y disruption unresolved
  31. 2024 Medium

    A non-RNA scaffolding role was reported: RBM10 nucleates a YBX1-PPM1B trimeric complex enabling PPM1B to dephosphorylate YBX1, restraining YBX1 nuclear translocation and breast cancer growth.

    Evidence Co-IP of triple complex, YBX1 phospho/fractionation Western blot, KD, PPM1B OE rescue, xenograft

    PMID:38246397

    Open questions at the time
    • Direct binding interfaces not mapped
    • Single-lab study
  32. 2025 High

    RBM10 splicing of cytoskeletal/ECM transcripts was mechanistically tied to metastasis: loss causes VCL/TNC/CD44 exon inclusion that activates RAC1 and drives invasion, reversible by isoform knockdown or RBM10 re-expression.

    Evidence RNA-seq, isoform-specific siRNA, RAC1-GTP pulldown, velocity/invasion assays, Rbm10KO mouse model, rescue

    PMID:39992626

    Open questions at the time
    • Direct binding to each target intron not mapped
    • How RAC1 is activated by the inclusion isoforms not defined
  33. 2025 Low

    A condensate-based transcriptional repression role was reported: RBM10 interacts with RORB in liquid condensates to repress its transactivation and downstream lysosomal/NF-κB programs.

    Evidence Co-IP, immunofluorescence, condensate assays, peptide inhibitor, tumor assays in neuroblastoma

    PMID:40899609

    Open questions at the time
    • Limited mechanistic depth; not independently confirmed
    • Direct condensate composition and stoichiometry undefined
  34. 2025 Medium

    RBM10's antiviral role was extended to HIV-1: Vpu degrades RBM10, and RBM10 inhibits replication by binding viral RNA, reducing incompletely spliced transcripts and promoting antiviral gene transcription.

    Evidence APEX2-proximity labeling + IP-MS, Co-IP, proteasome inhibitor rescue, RNA-IP, viral replication assays

    PMID:40742131

    Open questions at the time
    • Direct RBM10-Vpu interface not mapped
    • Mechanism of antiviral transcription promotion unclear
  35. 2026 Medium

    RBM10 was shown to drive circRNA biogenesis by binding intronic flanking sequences (preferentially 3') of circHIPK3/circSMARCA5 and acting with SF3B1, linking its exon-skipping activity to circularization in LUAD suppression.

    Evidence PAR-CLIP, RNA pulldown, splicing reporters, point mutants, Co-IP with SF3B1, fractionation, tumor assays

    PMID:41673707

    Open questions at the time
    • Genome-wide scope of circRNA regulation unknown
    • Mechanistic relationship between exon skipping and back-splicing not fully resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how RBM10's many activities — canonical U2-coupled splicing, Star-PAP 3'-end processing, replication fork protection, circRNA biogenesis, and non-RNA scaffolding — are coordinated and partitioned within a single protein, and which are direct versus indirect.
  • No unified structural/functional model across roles
  • Tissue- and context-specific deployment of each function undefined
  • Hierarchy between phosphorylation, NB sequestration, and partner choice unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 8 GO:0140098 catalytic activity, acting on RNA 5 GO:0045182 translation regulator activity 3 GO:0060090 molecular adaptor activity 3
Localization
GO:0005634 nucleus 4 GO:0005654 nucleoplasm 2 GO:0000228 nuclear chromosome 1 GO:0005886 plasma membrane 1
Pathway
R-HSA-1643685 Disease 4 R-HSA-8953854 Metabolism of RNA 4 R-HSA-168256 Immune System 2 R-HSA-74160 Gene expression (Transcription) 2 R-HSA-73894 DNA Repair 1
Partners
FILGAPHDAC1PRIM1RBM5SF3B1SRSF2STAR-PAP/TUT1YBX1
Complex memberships
Star-PAP (TUT1) 3'-end processing complexU2 snRNP

Evidence

Reading pass · 35 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 RBM10 binds pre-mRNA at sites in the vicinity of splice sites (identified by PAR-CLIP) and promotes exon skipping; loss-of-function and gain-of-function experiments in human cell lines, combined with minigene assays, established RBM10 as a regulator of alternative splicing, and splicing defects were confirmed in a patient carrying an RBM10 mutation. PAR-CLIP binding-site mapping, loss-of-function/gain-of-function experiments, minigene splicing assays, patient-derived cell analysis EMBO Molecular Medicine High 24000153
2014 RBM10 promotes exon skipping of Fas pre-mRNA and selection of an internal 5′-splice site in Bcl-x pre-mRNA, regulating alternative splicing of apoptosis-related genes; a consensus RBM10-binding sequence at 5′-splice sites of target exons was proposed. Minigene splicing assays, RBM10 knockdown/overexpression in human cell lines, RT-PCR FEBS Letters Medium 24530524
2016 RBM10 inhibits cell proliferation by promoting exon 9 skipping of NUMB pre-mRNA, generating a negative regulator of Notch signaling. The cancer-associated V354E mutation in the RRM2 domain disrupts this splicing activity without abolishing RRM2 binding to NUMB RNA regulatory sequences, and other lung adenocarcinoma mutations also compromise NUMB exon 9 regulation. Xenograft tumor growth assay (KD/OE), minigene splicing assays, RNA-binding assay, structural modeling, mutation analysis RNA Biology High 26853560
2017 RBM10 negatively autoregulates its own mRNA and protein expression and cross-regulates its paralog RBM5 by promoting alternative splicing-coupled nonsense-mediated mRNA decay (AS-NMD); skipping of exon 6 or 12 in RBM10 and exon 6 or 16 in RBM5 triggers NMD. LUAD-associated splice-site mutations abolishing exon inclusion correlated with reduced RBM10 RNA expression. Computational analysis, RT-PCR/qPCR, minigene assays, NMD inhibition experiments, patient mutation analysis Nucleic Acids Research High 28586478
2017 An RRM1-ZnF module of RBM10 recognizes a GGA-centered exonic motif to promote exon skipping, while the RRM2 domain recognizes a C-rich intronic 3′ sequence of NUMB exon 9. A polypeptide containing RRM1, ZnF1, and RRM2 in tandem recognizes a Fas exon 6 RNA sequence with ~20 nM affinity, explaining high-fidelity RNA recognition by cooperativity of domains. In vitro RNA-binding assays, NMR structure determination (RRM1, ZnF1, RRM2), domain deletion/combination experiments, splicing reporter assays Nucleic Acids Research High 28379442
2015 NMR structure determination revealed that the RBM10 OCRE sequence motif forms a 55-residue globular domain with an antiparallel arrangement of six β-strands containing Tyr triplets; this domain is distinct from RNA recognition motifs and is proposed to mediate spliceosome protein–protein interactions. NMR structure determination Structure High 26712279
2018 RBM10 cooperatively binds RNA through three domains (RRM1, ZnF1, RRM2): the combination recognizes a specific Fas exon 6 mRNA sequence with 20 nM affinity, whereas individual domains bind with micromolar affinity. NMR structures of RRM1, ZnF1, and the V354del isoform of RRM2 confirmed canonical RNA recognition elements. NMR structure determination, in vitro RNA-binding affinity measurements with domain combinations Biochemistry High 29450990
2018 RBM10 performs a splicing-independent function in the heart: it associates with the non-canonical poly(A) polymerase Star-PAP (TUT1) via its RRM2 domain binding to the Star-PAP catalytic domain, binds pre-mRNA 3′ UTRs, assembles the Star-PAP complex, and guides it to mRNAs encoding anti-hypertrophy regulators to control their 3′-end processing. RBM10 is downregulated during cardiac hypertrophy and heart failure; re-expression rescues cardiomyocyte hypertrophy. Co-IP, domain mapping (RRM2 binding to Star-PAP catalytic domain), 3′-end processing assays, RBM10 KD/OE in rat cardiomyoblasts (H9c2), cardiac hypertrophy model in Wistar rats Cell Reports High 30257214
2016 RBM10 iCLIP profiling in mouse embryonic mandibular cells showed preferential binding to intronic pre-mRNA regions consistent with a splicing role; RBM10 also binds spliceosomal snRNAs U2 and U12. RNA-seq of RBM10 KO mouse mandibular and ES cells revealed widespread alternative splicing changes in bound transcripts, and depletion of RBM10 in mouse ES cells caused proliferation defects and altered differentiation potential. iCLIP, RNA-seq (KO cells), CRISPR/Cas9 KO, proliferation assays, differentiation assays RNA Biology High 27763814
2024 RBM10 and its paralog RBM5 are subunits of the U2 snRNP, associating with precatalytic A/B-like spliceosomes at intronic branch sites genome-wide. A conserved peptide containing a zinc finger motif (separate from known functional domains) mediates the U2 snRNP interaction. Deletion of this peptide disrupts U2 association and renders RBM10 inactive for repression of many alternative exons. Biochemical isolation of chromatin-associated spliceosomal RNP complexes, MS proteomics, branch-site sequencing, domain deletion mutagenesis, splicing reporter assays Molecular Cell High 38537639
2017 Rbm10 controls appropriate splicing of Dnmt3b: Rbm10 deficiency decreases the non-enzymatic isoform Dnmt3b3 and increases the enzymatically active isoform Dnmt3b2. Both isoforms associate with NF-κB, and elevated Dnmt3b2 increases DNA methylation at NF-κB-responsive promoters, suppressing NF-κB-mediated transcription and inflammation in vivo and in vitro. RT-PCR (splicing isoform analysis), ChIP, promoter methylation assay, NF-κB reporter assay, RBM10 KO mice, in vitro Dnmt3b isoform overexpression International Immunology High 29309623
2020 Dengue virus NS5 polymerase interacts with RBM10 and triggers its proteasome-mediated degradation. RBM10 is responsible for exon 4 skipping in SAT1 pre-mRNA; its depletion during infection causes exon 4 inclusion generating an NMD-susceptible isoform, reducing SAT1 protein and limiting antiviral defense. RBM10 also interacts with viral RNA and RIG-I and promotes RIG-I ubiquitination (activating it), contributing to innate immune signaling. Co-IP (NS5-RBM10 interaction), proteasome inhibitor rescue, RBM10 KD/OE in infected cells, RT-PCR splicing assay, viral replication assays, RIG-I ubiquitination assay Nucleic Acids Research High 32432721
2013 S1-1/RBM10 contains multiple nuclear localization sequences (NLSs): a classical bipartite NLS (NLS1, aa 743–759), an NLS in the RRM1 region (NLS2, aa 60–136), and a novel NLS within the OCRE octamer-repeat region (NLS3, aa 481–540). These three NLSs act cooperatively; removal of all three renders the protein completely cytoplasmic. Nuclear localization is regulated in a cell-type-specific manner. Deletion and substitution mutagenesis, EGFP/FLAG fusion reporter assays, subcellular localization imaging Biology of the Cell Medium 23294349
2016 Src family tyrosine kinase Fyn induces translocation of RBM10 from the nucleus to cell peripheries in a kinase activity-dependent manner. At the cell periphery, RBM10 colocalizes with the Rac-specific GAP FilGAP and is required for peripheral FilGAP localization. RBM10 depletion abolishes FilGAP-mediated suppression of cell spreading and ruffle formation, suggesting RBM10 stimulates FilGAP RacGAP activity in a Src-regulated manner. Co-IP (RBM10-FilGAP interaction), siRNA knockdown, immunofluorescence localization, cell spreading assay, membrane ruffle assay, kinase-dead Fyn mutant PLoS One Medium 26751795
2019 RBM10 suppresses lung adenocarcinoma cell proliferation via a RAP1/AKT/CREB signaling pathway: RBM10 overexpression decreases RAP1 activation; EPAC stimulation/inhibition abolishes the effects of RBM10 KD/OE; and RBM10 reduces CREB phosphorylation through AKT, independently of MAPK/ERK and P38/MAPK pathways. cDNA microarray, RBM10 OE/KD, EPAC pharmacological modulation, Western blot (pCREB, pAKT), in vitro and in vivo proliferation assays Journal of Cellular and Molecular Medicine Medium 30955253
2022 RBM10 modulates alternative splicing of Bcl-x to regulate the ratio of proapoptotic Bcl-xS to antiapoptotic Bcl-xL isoforms. RBM10 deficiency decreases this ratio, diminishing EGFR inhibitor-mediated apoptosis. Coinhibition of Bcl-xL and mutant EGFR overcomes RBM10-deficiency-induced resistance. Patient-derived EGFR-mutant tumor models (in vitro and in vivo), RT-PCR (Bcl-x isoform ratio), apoptosis assays, genetic RBM10 inactivation, pharmacological Bcl-xL inhibition Journal of Clinical Investigation High 35579943
2021 RBM10 overexpression in HepG2 cells causes M-phase growth arrest with monopolar spindle due to impaired centriole duplication. Nuclear RBM10 sequesters centriole duplication regulators PLK4, STIL, and SAS6 into large nuclear domains, depleting them from centrioles. This requires nuclear localization (cytoplasmic NES-forced RBM10 does not cause arrest). RBM10 depletion increases cytoplasmic PLK4 and supernumerary centrioles in HepG2 but not A549 cells, indicating cell-type specificity. HepG2 RBM10 KO cell lines, doxycycline-inducible re-expression, flow cytometry (M-phase arrest), immunofluorescence (centriole markers), NES mutant forcing cytoplasmic localization, siRNA KD Genes to Cells Medium 31820547
2021 RBM10 nuclear localization is regulated by sequestration in S1-1 nuclear bodies (NBs). Two NB-targeting sequences (NBTSs) are identified: one in the KEKE motif region and one in the C2H2 zinc finger (ZnF). These NBTSs act synergistically; the C2H2 ZnF is also essential for alternative splicing regulation. NB-localization of RBM10 increases when cellular transcription decreases, suggesting NBs sequester RBM10 to control its splicing activity. Deletion mutagenesis, reporter constructs, immunofluorescence, transcription inhibition experiments International Journal of Molecular Sciences Medium 34638866
2017 RBM10 knockdown alters splicing of SMN2 pre-mRNA in multiple cancer and normal cell lines, resulting in preferential expression of the full-length exon-7-retaining SMN2 transcript and increased full-length SMN protein. Re-expression of RBM10 in a stable KD line reverted this effect, confirming specificity. siRNA KD, RT-PCR splicing array platform, Western blot, re-expression rescue, primary SMA patient fibroblasts BMC Molecular Biology Medium 28728573
2017 RBM5 post-transcriptionally regulates RBM10 expression via direct interaction with specific RBM10 splice variants, as demonstrated by RIP-Seq and Western blotting in an RBM5-null SCLC cell line. In this context, RBM10 promotes (rather than suppresses) cell proliferation and other transformation-associated processes. RNA immunoprecipitation sequencing (RIP-Seq), Western blotting, transcriptome analysis, functional cell proliferation assays PLoS One Medium 28662214
2021 In fission yeast, Rbm10 (ortholog of human RBM10) associates with the histone deacetylase Clr6 complex and chromatin remodelers important for heterochromatin silencing. Deletion of Rbm10 causes severe heterochromatin defects and significant reduction of Clr6 at heterochromatin, without major effects on genome-wide splicing, revealing a splicing-independent role in heterochromatin assembly. Proteomics (Rbm10 interactome), ChIP-seq (Clr6 localization), deep RNA-seq, genetic deletion, silencing reporter assays Epigenetics & Chromatin Medium 33468217
2024 RBM10 has a splicing-independent role in DNA replication fork stability: it associates with active DNA replication forks via interaction with DNA Primase Subunit 1 (PRIM1), recruits HDAC1 to facilitate H4K16 deacetylation, and maintains R-loop homeostasis. WEE1 inhibition is synthetically lethal with RBM10 deficiency (identified by CRISPR-Cas9 SL screen), and this lethality is mechanistically linked to replication stress. CRISPR-Cas9 synthetic lethality screen, DNA fiber assay (replication fork), iPOND/replication fork proteomics, HDAC1 recruitment assay, H4K16 acetylation ChIP, R-loop quantification, in vitro and in vivo WEE1 inhibitor treatment Nature Communications High 39080280
2024 RBM10 promotes exon 18 skipping of ASPM pre-mRNA by interacting with SRSF2. The C761Y mutation in the RBM10 C2H2-type zinc finger domain impairs its interaction with SRSF2, causing loss of ASPM exon 18 skipping, generating the ASPM203 isoform which stabilizes DVL2 and enhances β-catenin/Wnt signaling to promote cholangiocarcinoma progression. RNA-seq (alternative splicing), minigene reporter assays, Co-IP (RBM10-SRSF2 interaction with WT vs C761Y), Western blot, functional tumor assays Journal of Experimental & Clinical Cancer Research High 38576051
2021 RBM10 binds MALAT1 lncRNA (highest binding peak among ncRNAs by CLIP-Seq), and RBM10 inhibits invasion/migration of NSCLC by recruiting METTL3 to suppress m6A methylation of MALAT1, thereby affecting PI3K/AKT/mTOR pathway phosphorylation. CLIP-Seq, RIP assay (RBM10-MALAT1), MeRIP-qPCR (m6A methylation), Co-IP (RBM10-METTL3), transwell invasion/migration assays, Western blot Life Sciences Medium 36608868
2021 Star-PAP global mRNA association depends on RBM10: knockdown of RBM10 causes global loss of Star-PAP binding to target mRNAs and compromises 3′-end processing of Star-PAP target mRNAs while also regulating stability/turnover of another set of mRNAs. HITS-CLIP (Star-PAP binding landscape), RBM10 KD, 3′-end processing assays, mRNA stability assays International Journal of Molecular Sciences Medium 34576144
2024 cSrc kinase phosphorylates RBM10 at three tyrosine residues (Y81, Y500, Y971). This phosphorylation is induced during cardiac hypertrophy, promotes nuclear localization of RBM10 and its interaction with Star-PAP, and is required for anti-hypertrophy gene expression and 3′-end mRNA formation. Inhibition of cSrc or phospho-deficient RBM10 mutations prevent reversal of cardiac hypertrophy even when RBM10 levels are restored. In vitro kinase assay (cSrc phosphorylating RBM10), phospho-deficient mutants (Y→F), cSrc inhibitor treatment, isoproterenol-induced rat heart hypertrophy model, Co-IP (phospho-RBM10–Star-PAP), nuclear localization assay Life Sciences High 38309577
2023 RBM10 promotes exclusion of hTERT exons 7 and 8 to generate the non-functional hTERT-s isoform in pancreatic cancer, suppressing telomerase activity and telomere maintenance. This was confirmed by RNA-IP and RNA pulldown assays. RBM10 gain or loss significantly changed pancreatic cancer cell proliferation in vitro and in xenografts. RNA-IP, RNA pulldown, minigene/splicing assays, RBM10 OE/KD, telomerase activity assay, xenograft tumor growth American Journal of Cancer Research Medium 33520366
2020 miR-335 directly targets the 3′UTR of RBM10 mRNA (confirmed by luciferase reporter assay), downregulating RBM10 protein post-transcriptionally. This reduces RBM10-mediated exon skipping in NUMB pre-mRNA, increasing the Numb long isoform (Numb-L), which promotes endometrial cancer tumor growth in xenograft models. Luciferase reporter assay (miR-335 targeting RBM10 3′UTR), Western blot, xenograft mouse model, RT-PCR (NUMB splicing) Kaohsiung Journal of Medical Sciences Medium 31894898
2022 RBM10 interacts directly with NPTX1 mRNA (demonstrated by RIP assay) and regulates NPTX1 mRNA stability, as confirmed by actinomycin D mRNA decay experiments in pancreatic cancer cells. RIP assay, actinomycin D mRNA stability assay, RT-qPCR, Western blot Oncology Letters Low 35836482
2025 RBM10 loss in thyroid cancer causes exon inclusion events in cytoskeletal and ECM transcripts (vinculin VCL, tenascin C TNC, CD44), leading to RAC1 activation and increased cell velocity and invasiveness. Knockdown of the specific exon inclusion isoforms of VCL (reduced velocity), TNC, or CD44 (reduced invasiveness) reverses these phenotypes. In a mouse HrasG12V/Rbm10KO thyrocyte model, metastases develop and are reversed by RBM10 re-expression or combined knockdown of the three inclusion isoforms. RNA-seq (exon inclusion analysis), isoform-specific siRNA KD, RAC1-GTP pulldown assay, cell velocity assay, invasion assay, mouse genetic model (Rbm10KO), RBM10 re-expression rescue Journal of Experimental Medicine High 39992626
2025 RBM10 interacts with RORB transcription factor in liquid condensates in neuroblastoma cells, repressing RORB transactivation. A small peptide blocking the RBM10-RORB interaction suppresses lysosomal biogenesis, tumorigenesis, and aggressiveness by derepressing NR1D1/RIOK3-mediated suppression of NF-κB activity. Co-IP, immunofluorescence, liquid condensate assays, small-peptide inhibitor, functional tumor assays Advanced Science Low 40899609
2024 RBM10 forms a trimeric complex with YBX1 and phosphatase PPM1B; PPM1B dephosphorylates YBX1 within this complex. RBM10 knockdown attenuates the YBX1-PPM1B association, leading to elevated YBX1 phosphorylation and nuclear translocation, promoting breast cancer proliferation and migration. PPM1B overexpression reverses the tumorigenic effects of RBM10 depletion. Co-IP (triple complex), Western blot (YBX1 phosphorylation, nuclear fractionation), RBM10 KD, PPM1B OE rescue, xenograft assay Experimental Cell Research Medium 38246397
2025 HIV-1 Vpu interacts with RBM10 (identified by APEX2-proximity labeling + IP-MS) and promotes its degradation through the ubiquitin-proteasome pathway. RBM10 inhibits HIV-1 replication by binding to viral RNA and reducing incompletely spliced HIV-1 transcripts, and promotes transcription of antiviral genes. APEX2-proximity labeling + mass spectrometry, IP-MS, Co-IP, proteasome inhibitor rescue, RNA-IP (RBM10-viral RNA), viral replication assays mSystems Medium 40742131
2026 RBM10 directly binds intronic flanking sequences of circHIPK3 and circSMARCA5 pre-mRNAs (PAR-CLIP + RNA pulldown). Binding to the 3′ flanking region more efficiently promotes exon skipping and circularization than 5′ binding. RBM10 loss impairs formation of these circRNAs; RBM10 point mutants with defective exon skipping also fail to regulate circRNA production. Modulation of circHIPK3 and circSMARCA5 phenocopies RBM10 restoration in mutant LUAD cells. RBM10 interacts with SF3B1 as an upstream event governing circHIPK3 biogenesis. PAR-CLIP, RNA pulldown, splicing reporter assay, RBM10 point mutants, functional tumor assays, Co-IP (RBM10-SF3B1), subcellular fractionation Biomarker Research Medium 41673707
1996 DXS8237E (the gene later identified as RBM10) was isolated from human fetal brain cDNA, maps within 20 kb upstream of UBE1 at Xp11.23, and is subject to X inactivation (unlike its neighbor UBE1 which escapes X inactivation), as demonstrated in somatic cell hybrids containing an inactive human X chromosome. cDNA cloning, somatic cell hybrid analysis, Northern blot (expression), X-inactivation assay Genomics Medium 8808293

Source papers

Stage 0 corpus · 84 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate. American journal of human genetics 132 20451169
2017 RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. The American journal of surgical pathology 108 28296677
2017 Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical cancer research : an official journal of the American Association for Cancer Research 108 28634282
2016 Tumor suppressor properties of the splicing regulatory factor RBM10. RNA biology 97 26853560
2013 Integrative analysis revealed the molecular mechanism underlying RBM10-mediated splicing regulation. EMBO molecular medicine 94 24000153
2017 Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Scientific reports 78 28091594
2023 Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines 77 37509501
2006 Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. Journal of cellular biochemistry 72 16552754
2014 RBM10 regulates alternative splicing. FEBS letters 64 24530524
2020 Dengue virus targets RBM10 deregulating host cell splicing and innate immune response. Nucleic acids research 60 32432721
2011 Long-term survival in TARP syndrome and confirmation of RBM10 as the disease-causing gene. American journal of medical genetics. Part A 55 21910224
2022 Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. The Journal of clinical investigation 54 35579943
2017 Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3. The American journal of surgical pathology 51 28288037
2017 Autoregulation of RBM10 and cross-regulation of RBM10/RBM5 via alternative splicing-coupled nonsense-mediated decay. Nucleic acids research 49 28586478
2016 The RNA-binding landscape of RBM10 and its role in alternative splicing regulation in models of mouse early development. RNA biology 45 27763814
2021 RBM10: Structure, functions, and associated diseases. Gene 42 33515724
2019 RBM10 inhibits cell proliferation of lung adenocarcinoma via RAP1/AKT/CREB signalling pathway. Journal of cellular and molecular medicine 42 30955253
2018 A Splicing-Independent Function of RBM10 Controls Specific 3' UTR Processing to Regulate Cardiac Hypertrophy. Cell reports 42 30257214
2018 RBM10: Harmful or helpful-many factors to consider. Journal of cellular biochemistry 37 29274279
2021 RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis. Frontiers in oncology 36 33718153
2019 RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review. Histopathology 36 30908700
2017 An RRM-ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion. Nucleic acids research 36 28379442
2023 RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition. Cancer research 33 36853175
2017 RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PloS one 33 28662214
2016 Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern. Genes, chromosomes & cancer 33 26998913
2017 Rbm10 regulates inflammation development via alternative splicing of Dnmt3b. International immunology 31 29309623
2020 miR-335 modulates Numb alternative splicing via targeting RBM10 in endometrial cancer. The Kaohsiung journal of medical sciences 30 31894898
2024 The splicing regulators RBM5 and RBM10 are subunits of the U2 snRNP engaged with intron branch sites on chromatin. Molecular cell 26 38537639
2018 Functional role of RBM10 in lung adenocarcinoma proliferation. International journal of oncology 26 30483773
1996 A novel gene, DXS8237E, lies within 20 kb upstream of UBE1 in Xp11.23 and has a different X inactivation status. Genomics 26 8808293
2020 RBM10, a New Regulator of p53. Cells 25 32947864
2016 Src Family Tyrosine Kinase Signaling Regulates FilGAP through Association with RBM10. PloS one 25 26751795
2019 Alternative splicing of VEGFA is regulated by RBM10 in endometrial cancer. The Kaohsiung journal of medical sciences 23 31587503
2022 RBM10 regulates alternative splicing of lncRNA Neat1 to inhibit the invasion and metastasis of NSCLC. Cancer cell international 20 36335386
2017 Clinical diagnostic exome evaluation for an infant with a lethal disorder: genetic diagnosis of TARP syndrome and expansion of the phenotype in a patient with a newly reported RBM10 alteration. BMC medical genetics 20 28577551
2017 Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA. BMC molecular biology 17 28728573
2021 Phenotypic spectrum of the RBM10-mediated intellectual disability and congenital malformation syndrome beyond classic TARP syndrome features. Clinical genetics 16 33340101
2021 RBM10 regulates human TERT gene splicing and inhibits pancreatic cancer progression. American journal of cancer research 16 33520366
2021 RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. Frontiers in oncology 16 34367963
2015 Nuclear Magnetic Resonance Structure of a Novel Globular Domain in RBM10 Containing OCRE, the Octamer Repeat Sequence Motif. Structure (London, England : 1993) 16 26712279
2013 S1-1/RBM10: multiplicity and cooperativity of nuclear localisation domains. Biology of the cell 16 23294349
2023 RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC. Life sciences 15 36608868
2017 Increased cell apoptosis in human lung adenocarcinoma and in vivo tumor growth inhibition by RBM10, a tumor suppressor gene. Oncology letters 15 29085465
2013 Differential downregulation of Rbm5 and Rbm10 during skeletal and cardiac differentiation. In vitro cellular & developmental biology. Animal 15 24178303
2008 The small variant of the apoptosis-associated X-chromosome RBM10 gene is co-expressed with caspase-3 in breast cancer. Cancer genomics & proteomics 13 18820371
2022 NPTX1 inhibits pancreatic cancer cell proliferation and migration and enhances chemotherapy sensitivity by targeting RBM10. Oncology letters 12 35836482
2020 Protective effect of the RNA-binding protein RBM10 in hepatocellular carcinoma. European review for medical and pharmacological sciences 12 32572914
2020 A novel missense variant in RBM10 can cause a mild form of TARP syndrome with developmental delay and dysmorphic features. Clinical genetics 12 32812661
2024 RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma. Journal of experimental & clinical cancer research : CR 11 38576051
2023 An RBM10 and NF-κB interacting host lncRNA promotes JEV replication and neuronal cell death. Journal of virology 11 37991381
2021 Rbm10 facilitates heterochromatin assembly via the Clr6 HDAC complex. Epigenetics & chromatin 11 33468217
2018 Splicing Site Recognition by Synergy of Three Domains in Splicing Factor RBM10. Biochemistry 11 29450990
2024 Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma. Nature communications 10 39080280
2021 RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases. Genes, chromosomes & cancer 10 34358382
2018 Overexpression of RBM10 induces osteosarcoma cell apoptosis and inhibits cell proliferation and migration. Medecine sciences : M/S 10 30403180
2022 A Frameshift RBM10 Variant Associated With TARP Syndrome. Frontiers in genetics 9 35991558
2025 RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs. The Journal of experimental medicine 7 39992626
2021 Star-PAP RNA Binding Landscape Reveals Novel Role of Star-PAP in mRNA Metabolism That Requires RBM10-RNA Association. International journal of molecular sciences 7 34576144
2020 RBM10 regulates centriole duplication in HepG2 cells by ectopically assembling PLK4-STIL complexes in the nucleus. Genes to cells : devoted to molecular & cellular mechanisms 7 31820547
2021 Sequestration of RBM10 in Nuclear Bodies: Targeting Sequences and Biological Significance. International journal of molecular sciences 6 34638866
2025 RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma. Journal of experimental & clinical cancer research : CR 4 40069781
2025 Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-κB Signaling. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 4 40899609
2023 Functional insight into a neurodevelopmental disorder caused by missense variants in an RNA-binding protein, RBM10. Journal of human genetics 4 37268768
2022 A TARP Syndrome Phenotype Is Associated with a Novel Splicing Variant in RBM10. Genes 4 36421828
2019 RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report. Cancer genetics 4 30803556
2024 RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities. Experimental cell research 3 38246397
2023 The apoptotic splicing regulators RBM5 and RBM10 are subunits of the U2 snRNP engaged with intron branch sites on chromatin. bioRxiv : the preprint server for biology 3 37790489
2020 OCRE Domains of Splicing Factors RBM5 and RBM10: Tyrosine Ring-Flip Frequencies Determined by Integrated Use of 1 H NMR Spectroscopy and Molecular Dynamics Simulations. Chembiochem : a European journal of chemical biology 3 32975902
2024 Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinoma. Heliyon 2 38912481
2024 RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitness. bioRxiv : the preprint server for biology 2 39026820
2024 Down regulation of RBM10 promotes proliferation and metastasis via miR-224-5p/RBM10/p53 feedback loop in lung adenocarcinoma. Heliyon 2 39144991
2022 Conjunctival Perivascular Epithelioid Cell Neoplasm With RBM10-TFE3 Fusion Presenting as Recurrent Subconjunctival Hemorrhage. Ophthalmic plastic and reconstructive surgery 2 36095845
2025 RBM10 suppresses malignant transformation in endometrial cancer via the Hippo-YAP signaling pathway. American journal of translational research 1 40092130
2025 RBM10 suppresses colorectal cancer invasion by regulating LncRNA SNHG17 alternative splicing. Scientific reports 1 40229389
2025 RBM10 inhibits pancreatic cancer development by suppressing immune escape through PD-1 expression. Journal of Cancer 1 40740233
2024 Proto-oncogene cSrc-mediated RBM10 phosphorylation arbitrates anti-hypertrophy gene program in the heart and controls cardiac hypertrophy. Life sciences 1 38309577
2026 RBM10 modulation of circRNA biogenesis contributes to its tumor suppressor role in lung adenocarcinoma. Biomarker research 0 41673707
2026 Fatal Disease Progression Driven by Acquired MET Amplification After EGFR-TKI Therapy in EGFR- and RBM10-Mutant Lung Adenocarcinoma. Cancer management and research 0 41878697
2026 Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation. Clinical lung cancer 0 41934032
2026 RBM10 suppresses porcine epidemic diarrhea virus replication by degrading nonstructural protein 3 through selective autophagy. Veterinary microbiology 0 42229174
2025 Splicing factor RBM10 loss fuels thyroid cancer metastasis. The Journal of experimental medicine 0 39992625
2025 Gastric carcinoma harbouring loss‑of‑function mutations in the PIK3R1, ATRX and RBM10 genes exhibits diverse histological features associated with EBV infection and TP53 inactivation: A case report. Oncology letters 0 40213088
2025 HIV-1 Vpu interacts with RBM10 to promote HIV-1 infection. mSystems 0 40742131
2025 MALAT1 overexpression contributes to choriocarcinoma by binding with RBM10 and promoting p53 degradation. Placenta 0 40774083

Missed literature

Know a paper Affinage missed for RBM10? Flag it for the maintainers and the community.

No submissions yet.